Navigation Links
Trevena Granted Key Composition of Matter Patent for TRV027 in U.S.
Date:7/17/2013

KING OF PRUSSIA, Pa., July 17, 2013 /PRNewswire/ -- Trevena, Inc., (Trevena) a clinical stage pharmaceutical company and the leader in the discovery and development of G-protein coupled receptor (GPCR) biased ligands, announced today that the United States Patent and Trademark Office has granted Trevena a composition of matter patent covering its development product TRV027.  United States Patent No. 8,486,885 entitled "Beta-Arrestin Effectors and Composition and Methods of Use Thereof," is expected to provide coverage for TRV027 until at least July 2031.    

TRV027 is an experimental intravenous drug for the treatment of acute decompensated heart failure (ADHF), currently in mid-stage clinical trials.  It is a novel beta-arrestin biased ligand of the angiotensin II type 1 receptor that combines the proven benefits of angiotensin blockade with new beta-arrestin-mediated biology to preserve cardiac and renal function.  Trevena recently entered into a collaborative licensing option agreement for the development of TRV027 with Forest Laboratories Inc. (NYSE: FRX).  The company expects to commence a 500-patient multi-center Phase 2b clinical trial for TRV027 in ADHF patients by year end.

"This core patent provides the foundation for broad and enforceable intellectual property protection for TRV027, and is followed by a series of patent applications made by Trevena to protect our growing pipeline of GPCR biased ligands in key markets around the world,"  said Maxine Gowen, Trevena's President and Chief Executive Officer.  David Solomon, Forest's SVP of Corporate Development & Strategic Planning, and a Board member at Trevena, added, "This issued patent enhances the value potential of TRV027, and provides an essential platform from which to drive its commercialization."  

Trevena recently presented the results of
'/>"/>

SOURCE Trevena, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Trevena, Inc. and Forest Laboratories Announce a Collaborative Agreement For Development of TRV027 for the Treatment of Acute Heart Failure
2. Trevena, Inc. to Present at the 12th Annual Needham Healthcare Conference
3. CorMedix Granted Extension of NYSE MKT Listing
4. QRxPharma Granted US Patent On Hybrid Opioids
5. Mapi Pharma Granted United States Patent Covering Glatiramer Depot for Multiple Sclerosis
6. Omeros Ophthalmology Product OMS302 Granted Eligibility for European Centralized Review
7. Bayers Investigational Riociguat Granted U.S. FDA Priority Review for Pulmonary Arterial Hypertension and Inoperable or Persistent/Recurrent Chronic Thromboembolic Pulmonary Hypertension
8. Oramed Pharmaceuticals Granted Japanese Patent for its Core Technology in Oral Delivery of Proteins
9. Cedarburg Hauser Granted DEA Registration for Denver Manufacturing Facility
10. KAHR Medical Granted U.S. Patent Approval for One of its Lead Products in Development, KAHR-101
11. US Patent Granted to RBC Life Sciences for Supplement that Supports Cognitive Function
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... , Oct. 22, 2014 InVivo Therapeutics ... MA is revolutionizing spinal cord injury (SCI) ... been shown to outperform in tissue regrowth in the ... scaffold.  Made from an FDA approved polymer, the scaffold ... it harmless to the human body. NVIV has recently ...
(Date:10/22/2014)... 22, 2014 WHEN: Wednesday, October 29, 2014 ... available at: http://bit.ly/1yStiU9 SPEAKERS: Visionary ... Visionary Innovation Research Group Senior Research Analyst ... materials, nanobots and flexible electronics are among ... our lives in the coming decades. These ...
(Date:10/22/2014)... -- Provectus Biopharmaceuticals, Inc. (NYSEMKT: PVCT) specializes in developing ... for cancer, is designed for injection into solid tumors ... focus is on melanoma, breast cancer and cancers of ... PV-10 as a therapy for metastatic melanoma, and of ... psoriasis. This summer, the Company signed ...
Breaking Medicine Technology:InVivo Therapeutics Analyst Coverage Initiated: Analyst Report by BrokerBank Securities, Inc. 2InVivo Therapeutics Analyst Coverage Initiated: Analyst Report by BrokerBank Securities, Inc. 3Futuristic Technologies That Will Transform Our World Beyond 2030 2Futuristic Technologies That Will Transform Our World Beyond 2030 3Futuristic Technologies That Will Transform Our World Beyond 2030 4Provectus Biopharmaceuticals Looks at the Asian Markets: Analyst Coverage by Small Cap Traders 2
... 8 , - Glivec(R) (imatinib) ... KIT (CD117)-Positive Gastrointestinal Stromal Tumours,(GIST), who are at Significant Risk ... - Use of Glivec(R) After Surgery Significantly Reduces Risk ... After Surgery, 50% of patients Will Experience Their,Cancer Returning Within ...
... guidance regarding strategic transaction processSAN DIEGO, May 7 ... ANX ) today announced results from its bioequivalence ... determined to have comparable overall safety as Taxotere(R), ... groups in severe toxicities. However, pharmacokinetic equivalence, ...
Cached Medicine Technology:Glivec(R) is the First Adjuvant Treatment Approved in the UK to Delay Return of Gastrointestinal Cancer After Surgery 2Glivec(R) is the First Adjuvant Treatment Approved in the UK to Delay Return of Gastrointestinal Cancer After Surgery 3Glivec(R) is the First Adjuvant Treatment Approved in the UK to Delay Return of Gastrointestinal Cancer After Surgery 4Glivec(R) is the First Adjuvant Treatment Approved in the UK to Delay Return of Gastrointestinal Cancer After Surgery 5Glivec(R) is the First Adjuvant Treatment Approved in the UK to Delay Return of Gastrointestinal Cancer After Surgery 6ADVENTRX Announces Results From ANX-514 Bioequivalence Study 2ADVENTRX Announces Results From ANX-514 Bioequivalence Study 3ADVENTRX Announces Results From ANX-514 Bioequivalence Study 4ADVENTRX Announces Results From ANX-514 Bioequivalence Study 5
(Date:10/25/2014)... Interrupting blood supply to an arm or a leg before ... surgery, according to a new study. "During heart ... heart to be able to operate on it. After some ... to produce energy because it doesn,t get oxygen. When we ... as an arm or a leg, the body prepares for ...
(Date:10/25/2014)... News) -- Not getting the right amount of sleep ... study suggests. Those who sleep less or more ... may be more prone to developing the chronic condition, ... study authors concluded that duration and quality of sleep ... inflammatory bowel diseases. "Both short and long durations ...
(Date:10/25/2014)... large influx of international aid is needed, and soon, ... of deaths from the widening Ebola crisis, a team ... specially designed mathematical model, the researchers looked at the ... populated county of hard-hit Liberia -- Montserrado County, home ... said that if international aid isn,t delivered to Liberia ...
(Date:10/25/2014)... HealthDay Reporter FRIDAY, Oct. ... developed that spot increased risks for certain cancers, one might ... screened. But a new study suggests that, at least ... found out their genes doubled their risk of colon cancer ... get screened. "It didn,t make any difference, not at ...
(Date:10/22/2014)... Pennsylvania (PRWEB) October 22, 2014 At ... and uncertainty among parents and athletes at all levels, ... working to change the current discussion where two powerful ... are evidence-based therapies that result in full recoveries every ... to one based in fact and research, UPMC and ...
Breaking Medicine News(10 mins):Health News:Brief Interruption of Blood Supply to Limb Might Aid Heart Surgery: Study 2Health News:Sleep Duration Linked to Ulcerative Colitis Risk in Study 2Health News:Experts Predict 'Catastrophic' Ebola Epidemic in West Africa if Aid Delayed 2Health News:Knowing Genetic Risk for Cancer May Not Change Behavior 2Health News:University of Pittsburgh Medical Center Launches Initiative to Emphasize Concussions Are Treatable 2Health News:University of Pittsburgh Medical Center Launches Initiative to Emphasize Concussions Are Treatable 3Health News:University of Pittsburgh Medical Center Launches Initiative to Emphasize Concussions Are Treatable 4
... S. Department of Health and Human Services (HHS) and ... launch National Infant Immunization Week (NIIW) with events// April ... are expected to participate in NIIW by sponsoring activities ... ,CDC and HHS will collaborate with state ...
... Brodie Campbell are still in shock and grief over the ... have reportedly brought in grief counselors to help students deal ... student at his school- Dr. Charles Best Secondary School in ... has now confirmed the reason of death as bacterial meningitis. ...
... losing its forests to over-exploitation, will get help in ... which signed up the// country as a member this ... Analysis (IIASA), Austria - a non-governmental research organization that ... the context of global change - has said it ...
... Institute of Medical Sciences (AIIMS) has developed artificial testis, ... genitals.// ,Doctors at the premier referral hospital ... such problems, achieving 100 percent success. ,"We ... patients with not a single case of rejection. From ...
... scam burst into the open in Paris, Dr. Brian ... three months by the// Californian state authorities. ... Area Laboratory Co-Operative that allegedly provided steroids to top ... five years' probation and ordered to undergo a psychiatric ...
... too serious a matter to be left in the hands of ... the care of labour department officials. At least such// seems to ... that agencies like the Occupational Safety and Health Administration ... than with the safety of the workers themselves. ...
Cached Medicine News:Health News:National Infant Immunization Week Urges Parents to Vaccinate On Time 2Health News:India to Protect Its Forests With the Aid of Austrian NGO 2Health News:Artificial Testis Developed by AIIMS a Boon to Suffering Patients 2Health News:US Psychiatrist Suspended from Practicing Medicine for Involvement in Doping Scam 2Health News:US Psychiatrist Suspended from Practicing Medicine for Involvement in Doping Scam 3Health News:Overseeing Agency Indifferent to Workplace Safety in US 2
View Mex-3 is designed for out-patient surgery, hospital rounds and house calls....
Headlight module is mounted on UltraLite Plus headband or sweatband....
It is a magnifying headlight perfect for all applications and procedures where clear magnification and a natural white light increase accuracy and productivity....
It is a magnifying headlight perfect for all applications and procedures where clear magnification and a natural white light increase accuracy and productivity....
Medicine Products: